Last update June 25, 2022

3-Ethyl-1,5,6,7-tetrahydro-2-methyl-5-(morpholinomethyl)indol-4-one hydrochloride

Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

It is a typical, first generation antipsychotic with general properties similar to those of chlorpromazine, that is used for the treatment of schizophrenia and other psychoses. Oral or intramuscular administration.

Since the last update we have not found published data on its excretion in breastmilk.

The few known pharmacokinetic data do not allow to predict the possible passage into breast milk.

Product with very few bibliographical references and marketed in few countries.

It can cause galactorrhea. (Wesp 1979, Kahn 1979)

Until there is more published data on this drug in relation to breastfeeding, safer known alternatives are preferable, especially during the neonatal period and in cases of prematurity.


See below the information of this related product:

Alternatives

  • Lurasidone (Safe product and/or breastfeeding is the best option.)
  • Olanzapine (Safe product and/or breastfeeding is the best option.)
  • Quetiapine Fumarate (Safe product and/or breastfeeding is the best option.)
  • Ziprasidone (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

3-Ethyl-1,5,6,7-tetrahydro-2-methyl-5-(morpholinomethyl)indol-4-one hydrochloride is Molindone Hydrochloride in Chemical name.

Is written in other languages:

Groups

3-Ethyl-1,5,6,7-tetrahydro-2-methyl-5-(morpholinomethyl)indol-4-one hydrochloride belongs to these groups or families:

Tradenames

Main tradenames from several countries containing 3-Ethyl-1,5,6,7-tetrahydro-2-methyl-5-(morpholinomethyl)indol-4-one hydrochloride in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 313 daltons
pKa 15.43 -
Tmax 0.6 - 1.1 hours
2 hours

References

  1. Zetin M, Cramer M, Garber D, Plon L, Paulshock M, Hoffman HE, Schary WL. Bioavailability of oral and intramuscular molindone hydrochloride in schizophrenic patients. Clin Ther. 1985;7(2):169-75. Abstract
  2. Wesp CE Jr, Annitto W, Feinsod R. Galactorrhea associated with molindone. Am J Psychiatry. 1979 Jul;136(7):975. No abstract available. Abstract
  3. Kahn JL. More on galactorrhea associated with molindone. Am J Psychiatry. 1979 Dec;136(12):1617-8. No abstract available. Abstract

Total visits

569

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM